Valspodar
- Generic Name
- Valspodar
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C63H111N11O12
- CAS Number
- 121584-18-7
- Unique Ingredient Identifier
- Q7ZP55KF3X
- Background
Valspodar has been used in trials studying the treatment of Cancer, Sarcoma, Leukemia, Lymphoma, and Breast Cancer, among others.
- Associated Conditions
- -
- Associated Therapies
- -
Paclitaxel With or Without PSC 833 in Treating Patients With Metastatic Breast Cancer
- Conditions
- First Posted Date
- 2004-09-03
- Last Posted Date
- 2010-01-06
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 70
- Registration Number
- NCT00002937
- Locations
- πΊπΈ
University of California Davis Cancer Center, Sacramento, California, United States
πΊπΈBeckman Research Institute, City of Hope, Duarte, California, United States
π¨π¦Toronto Sunnybrook Regional Cancer Centre, Toronto, Ontario, Canada
S9918 PSC 833, Daunorubicin, and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
- Conditions
- First Posted Date
- 2004-06-18
- Last Posted Date
- 2015-03-06
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 55
- Registration Number
- NCT00004217
- Locations
- πΊπΈ
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
πΊπΈVeterans Affairs Outpatient Clinic - Martinez, Martinez, California, United States
πΊπΈUniversity of Texas Medical Branch, Galveston, Texas, United States
Drug Resistance Inhibition in Treating Women With Recurrent or Metastatic Breast Cancer
- Conditions
- First Posted Date
- 2004-05-12
- Last Posted Date
- 2023-06-07
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Target Recruit Count
- 36
- Registration Number
- NCT00002826
- Locations
- πΊπΈ
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
πΊπΈKimball Medical Center, Lakewood, New Jersey, United States
πΊπΈSt. Francis Medical Center, Trenton, New Jersey, United States
Combination Chemotherapy Plus PSC-833 in Treating Children With Refractory or Relapsed Acute Leukemia
- Conditions
- Interventions
- First Posted Date
- 2004-04-29
- Last Posted Date
- 2013-02-01
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 3
- Registration Number
- NCT00002912
- Locations
- πΊπΈ
Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
πΊπΈChildren's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
πΊπΈSimmons Cancer Center - Dallas, Dallas, Texas, United States
Combination Chemotherapy With or Without Valspodar in Treating Patients With Previously Untreated Acute Myeloid Leukemia
- Conditions
- Adult Acute Megakaryoblastic Leukemia (M7)Adult Acute Minimally Differentiated Myeloid Leukemia (M0)Adult Acute Monoblastic Leukemia (M5a)Adult Acute Monocytic Leukemia (M5b)Adult Acute Myeloblastic Leukemia With Maturation (M2)Adult Acute Myeloblastic Leukemia Without Maturation (M1)Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
- Interventions
- First Posted Date
- 2003-10-28
- Last Posted Date
- 2013-06-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 640
- Registration Number
- NCT00003190
- Locations
- πΊπΈ
Cancer and Leukemia Group B, Chicago, Illinois, United States
Combination Chemotherapy With or Without PSC 833 in Treating Patients With Relapsed or Refractory Multiple Myeloma
- Conditions
- First Posted Date
- 2003-07-09
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Registration Number
- NCT00002878
- Locations
- πΊπΈ
CCOP - Christiana Care Health Services, Wilmington, Delaware, United States
π¨π¦CancerCare Manitoba, Winnipeg, Manitoba, Canada
π¨π¦Cancer Care Ontario-London Regional Cancer Centre, London, Ontario, Canada
Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-12-18
- Lead Sponsor
- Leukemia Research Fund
- Target Recruit Count
- 2000
- Registration Number
- NCT00005823
- Locations
- π¬π§
University Hospital of Wales, Cardiff, Wales, United Kingdom
π¬π§University College Hospital, London, England, United Kingdom
π¬π§Queen Elizabeth Hospital at University of Birmingham, Birmingham, England, United Kingdom
Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia
- Conditions
- Adult Acute Eosinophilic LeukemiaAdult Acute Erythroid Leukemia (M6)Adult Acute Megakaryoblastic Leukemia (M7)Adult Acute Basophilic LeukemiaAdult Acute Minimally Differentiated Myeloid Leukemia (M0)Adult Acute Monoblastic Leukemia (M5a)Adult Acute Monoblastic Leukemia and Acute Monocytic Leukemia (M5)Adult Acute Monocytic Leukemia (M5b)Adult Acute Myeloblastic Leukemia With Maturation (M2)Adult Acute Myeloblastic Leukemia Without Maturation (M1)
- Interventions
- Drug: cytarabineBiological: aldesleukinOther: clinical observationDrug: daunorubicin hydrochlorideBiological: filgrastimDrug: etoposideOther: pharmacological studyDrug: valspodarDrug: busulfanProcedure: autologous hematopoietic stem cell transplantationProcedure: peripheral blood stem cell transplantation
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 720
- Registration Number
- NCT00006363
- Locations
- πΊπΈ
Cancer and Leukemia Group B, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.